NASDAQ:EXAS

Exact Sciences Competitors

$125.54
-2.96 (-2.30 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$123.50
Now: $125.54
$128.50
50-Day Range
$116.57
MA: $131.34
$147.81
52-Week Range
$63.32
Now: $125.54
$159.54
Volume1.22 million shs
Average Volume1.79 million shs
Market Capitalization$21.23 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.64

Competitors

Exact Sciences (NASDAQ:EXAS) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying EXAS stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Exact Sciences, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

Exact Sciences (NASDAQ:EXAS) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk.

Earnings and Valuation

This table compares Exact Sciences and Amgen's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Exact Sciences$876.29 million24.22$-83,990,000.00($1.49)-84.26
Amgen$23.36 billion6.14$7.84 billion$14.8216.80

Amgen has higher revenue and earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for Exact Sciences and Amgen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Exact Sciences031102.79
Amgen0101402.58

Exact Sciences currently has a consensus price target of $150.3333, indicating a potential upside of 19.75%. Amgen has a consensus price target of $259.4091, indicating a potential upside of 4.20%. Given Exact Sciences' stronger consensus rating and higher possible upside, research analysts clearly believe Exact Sciences is more favorable than Amgen.

Profitability

This table compares Exact Sciences and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Exact Sciences-25.27%-11.71%-6.74%
Amgen29.42%95.55%15.52%

Institutional & Insider Ownership

90.4% of Exact Sciences shares are held by institutional investors. Comparatively, 75.2% of Amgen shares are held by institutional investors. 1.8% of Exact Sciences shares are held by insiders. Comparatively, 0.4% of Amgen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk & Volatility

Exact Sciences has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500.

Summary

Amgen beats Exact Sciences on 8 of the 14 factors compared between the two stocks.

Exact Sciences (NASDAQ:EXAS) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, analyst recommendations, risk and dividends.

Insider and Institutional Ownership

90.4% of Exact Sciences shares are owned by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are owned by institutional investors. 1.8% of Exact Sciences shares are owned by company insiders. Comparatively, 0.1% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for Exact Sciences and Gilead Sciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Exact Sciences031102.79
Gilead Sciences191402.54

Exact Sciences currently has a consensus price target of $150.3333, indicating a potential upside of 19.75%. Gilead Sciences has a consensus price target of $97.2308, indicating a potential upside of 49.33%. Given Gilead Sciences' higher probable upside, analysts clearly believe Gilead Sciences is more favorable than Exact Sciences.

Profitability

This table compares Exact Sciences and Gilead Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Exact Sciences-25.27%-11.71%-6.74%
Gilead Sciences5.48%37.77%12.76%

Earnings & Valuation

This table compares Exact Sciences and Gilead Sciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Exact Sciences$876.29 million24.22$-83,990,000.00($1.49)-84.26
Gilead Sciences$22.45 billion3.65$5.39 billion$6.1410.60

Gilead Sciences has higher revenue and earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Exact Sciences has a beta of 1.64, suggesting that its share price is 64% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500.

Summary

Gilead Sciences beats Exact Sciences on 9 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Exact Sciences (NASDAQ:EXAS) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability.

Profitability

This table compares Vertex Pharmaceuticals and Exact Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals38.51%28.55%20.68%
Exact Sciences-25.27%-11.71%-6.74%

Volatility and Risk

Vertex Pharmaceuticals has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Exact Sciences has a beta of 1.64, suggesting that its stock price is 64% more volatile than the S&P 500.

Earnings and Valuation

This table compares Vertex Pharmaceuticals and Exact Sciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion13.32$1.18 billion$4.2949.73
Exact Sciences$876.29 million24.22$-83,990,000.00($1.49)-84.26

Vertex Pharmaceuticals has higher revenue and earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for Vertex Pharmaceuticals and Exact Sciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals042112.88
Exact Sciences031102.79

Vertex Pharmaceuticals currently has a consensus target price of $293.1250, indicating a potential upside of 37.39%. Exact Sciences has a consensus target price of $150.3333, indicating a potential upside of 19.75%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Exact Sciences.

Institutional & Insider Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 90.4% of Exact Sciences shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 1.8% of Exact Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Vertex Pharmaceuticals beats Exact Sciences on 12 of the 15 factors compared between the two stocks.

Exact Sciences (NASDAQ:EXAS) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk and earnings.

Valuation and Earnings

This table compares Exact Sciences and Regeneron Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Exact Sciences$876.29 million24.22$-83,990,000.00($1.49)-84.26
Regeneron Pharmaceuticals$7.86 billion6.47$2.12 billion$21.4722.13

Regeneron Pharmaceuticals has higher revenue and earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Exact Sciences and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Exact Sciences-25.27%-11.71%-6.74%
Regeneron Pharmaceuticals38.28%28.97%20.11%

Insider and Institutional Ownership

90.4% of Exact Sciences shares are owned by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. 1.8% of Exact Sciences shares are owned by insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Exact Sciences has a beta of 1.64, suggesting that its stock price is 64% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for Exact Sciences and Regeneron Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Exact Sciences031102.79
Regeneron Pharmaceuticals051412.80

Exact Sciences currently has a consensus target price of $150.3333, suggesting a potential upside of 19.75%. Regeneron Pharmaceuticals has a consensus target price of $637.2083, suggesting a potential upside of 34.10%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Exact Sciences.

Summary

Regeneron Pharmaceuticals beats Exact Sciences on 12 of the 15 factors compared between the two stocks.

Exact Sciences (NASDAQ:EXAS) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations and risk.

Institutional and Insider Ownership

90.4% of Exact Sciences shares are owned by institutional investors. Comparatively, 83.5% of Biogen shares are owned by institutional investors. 1.8% of Exact Sciences shares are owned by company insiders. Comparatively, 0.5% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Exact Sciences and Biogen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Exact Sciences031102.79
Biogen5141202.23

Exact Sciences currently has a consensus target price of $150.3333, suggesting a potential upside of 19.75%. Biogen has a consensus target price of $303.5517, suggesting a potential upside of 13.19%. Given Exact Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Exact Sciences is more favorable than Biogen.

Earnings & Valuation

This table compares Exact Sciences and Biogen's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Exact Sciences$876.29 million24.22$-83,990,000.00($1.49)-84.26
Biogen$14.38 billion2.84$5.89 billion$33.577.99

Biogen has higher revenue and earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Exact Sciences has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500.

Profitability

This table compares Exact Sciences and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Exact Sciences-25.27%-11.71%-6.74%
Biogen35.63%51.00%23.54%

Summary

Biogen beats Exact Sciences on 8 of the 14 factors compared between the two stocks.

Alexion Pharmaceuticals (NASDAQ:ALXN) and Exact Sciences (NASDAQ:EXAS) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, valuation, profitability, analyst recommendations, earnings and dividends.

Insider & Institutional Ownership

87.3% of Alexion Pharmaceuticals shares are held by institutional investors. Comparatively, 90.4% of Exact Sciences shares are held by institutional investors. 4.0% of Alexion Pharmaceuticals shares are held by company insiders. Comparatively, 1.8% of Exact Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Alexion Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Exact Sciences has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500.

Earnings and Valuation

This table compares Alexion Pharmaceuticals and Exact Sciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alexion Pharmaceuticals$4.99 billion6.83$2.40 billion$9.7415.91
Exact Sciences$876.29 million24.22$-83,990,000.00($1.49)-84.26

Alexion Pharmaceuticals has higher revenue and earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Alexion Pharmaceuticals and Exact Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alexion Pharmaceuticals16.32%23.16%14.76%
Exact Sciences-25.27%-11.71%-6.74%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Alexion Pharmaceuticals and Exact Sciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alexion Pharmaceuticals017512.30
Exact Sciences031102.79

Alexion Pharmaceuticals currently has a consensus target price of $153.8636, indicating a potential downside of 0.74%. Exact Sciences has a consensus target price of $150.3333, indicating a potential upside of 19.75%. Given Exact Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Exact Sciences is more favorable than Alexion Pharmaceuticals.

Summary

Alexion Pharmaceuticals beats Exact Sciences on 9 of the 15 factors compared between the two stocks.


Exact Sciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.3$248.95-0.8%$143.35 billion$23.36 billion20.08Analyst Revision
Gilead Sciences logo
GILD
Gilead Sciences
2.8$65.11-0.1%$81.98 billion$22.45 billion67.12
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.2$213.35-1.4%$55.46 billion$4.16 billion26.94Insider Selling
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$475.17-0.3%$50.91 billion$7.86 billion17.37News Coverage
Biogen logo
BIIB
Biogen
1.9$268.17-0.9%$40.85 billion$14.38 billion8.88
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$155.01-0.3%$34.08 billion$4.99 billion36.22
Seagen logo
SGEN
Seagen
1.7$142.85-1.1%$25.90 billion$916.71 million56.24Insider Selling
News Coverage
Incyte logo
INCY
Incyte
1.9$79.96-1.1%$17.58 billion$2.16 billion-50.93News Coverage
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$138.23-3.1%$16.22 billion$219.75 million-17.65News Coverage
Gap Down
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$77.07-1.5%$14.01 billion$1.70 billion17.64Insider Selling
News Coverage
Novavax logo
NVAX
Novavax
1.6$179.74-1.9%$13.28 billion$18.66 million-34.43Insider Selling
Gap Up
Repligen logo
RGEN
Repligen
1.5$206.10-0.9%$11.29 billion$270.24 million251.34News Coverage
United Therapeutics logo
UTHR
United Therapeutics
1.5$203.36-1.3%$9.06 billion$1.45 billion19.24Analyst Report
Analyst Revision
News Coverage
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$93.35-0.7%$8.77 billion$788.10 million100.38Analyst Downgrade
Exelixis logo
EXEL
Exelixis
1.9$23.12-1.0%$7.21 billion$967.78 million48.17
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$42.77-1.3%$6.13 billion$195.99 million267.31
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$42.36-0.8%$5.97 billion$1.12 billion88.25
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.35-1.6%$4.12 billion$1.11 billion24.87Analyst Report
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$66.29-0.3%$4.00 billion$806.43 million-9.39
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$49.41-0.6%$3.44 billion$36.13 million-73.75Unusual Options Activity
News Coverage
Alkermes logo
ALKS
Alkermes
1.2$19.02-0.2%$3.03 billion$1.17 billion-41.35Unusual Options Activity
OPKO Health logo
OPK
OPKO Health
1.9$4.18-2.2%$2.80 billion$901.90 million-23.22
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$153.44-1.4%$2.55 billion$120.28 million-154.99Analyst Upgrade
News Coverage
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.19-0.9%$2.43 billion$182.24 million-7.99News Coverage
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$28.16-1.1%$2.12 billion$638.60 million-10.83
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$117.02-0.4%$1.88 billionN/A-10.57
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.5$10.21-1.9%$1.81 billion$48.83 million-13.43
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$10.19-1.5%$1.64 billion$428.41 million14.77
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.02-2.1%$1.58 billion$102.43 million-18.37Analyst Upgrade
Gap Down
Codexis logo
CDXS
Codexis
1.1$24.00-2.6%$1.55 billion$68.46 million-68.57Insider Selling
Gap Down
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.56-3.8%$1.51 billion$82.27 million-18.44Unusual Options Activity
News Coverage
Gap Down
Innoviva logo
INVA
Innoviva
1.4$11.70-1.6%$1.19 billion$261.02 million5.97
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.07-1.0%$1.14 billion$35.22 million-7.35
Curis logo
CRIS
Curis
1.3$11.50-2.9%$1.05 billion$10 million-14.02Gap Down
MannKind logo
MNKD
MannKind
1.4$4.24-1.9%$1.05 billion$63.04 million-20.19News Coverage
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.25-2.2%$891.85 million$227.19 million45.14Analyst Upgrade
Gap Down
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$23.19-2.0%$842.45 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$20.71-1.4%$820.43 million$3.57 million-9.29Analyst Upgrade
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.37-1.1%$775.18 million$322.07 million-5.11
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$22.17-5.3%$731.97 million$252 million-2.27Gap Down
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.32-2.1%$714.48 million$150,000.00-4.74Gap Down
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$6.23-5.6%$651.22 million$143.01 million-1.19Gap Down
Agenus logo
AGEN
Agenus
1.6$2.79-0.0%$570.05 million$150.05 million-2.56
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.26-1.8%$554.59 million$59.29 million-21.73
Fortress Biotech logo
FBIO
Fortress Biotech
1.4$5.44-10.3%$516.29 million$36.63 million-6.40Analyst Downgrade
High Trading Volume
Unusual Options Activity
Analyst Revision
News Coverage
Gap Up
Verastem logo
VSTM
Verastem
1.1$2.76-1.8%$473.80 million$17.46 million-1.96Analyst Report
Analyst Revision
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.07-3.9%$471.95 million$109.33 million-2.26Gap Down
Geron logo
GERN
Geron
1.4$1.48-2.7%$471.43 million$460,000.00-4.23Analyst Report
News Coverage
Gap Down
Molecular Templates logo
MTEM
Molecular Templates
2.0$8.23-0.4%$461.31 million$22.27 million-4.03Analyst Report
Insider Buying
High Trading Volume
Unusual Options Activity
Analyst Revision
XOMA logo
XOMA
XOMA
1.3$38.99-0.8%$438.75 million$18.37 million-35.13Analyst Upgrade
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.